中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
19期
14-16
,共3页
左西孟旦%西地那非%慢性心力衰竭%肺动脉压升高
左西孟旦%西地那非%慢性心力衰竭%肺動脈壓升高
좌서맹단%서지나비%만성심력쇠갈%폐동맥압승고
Levosimendan%Sildenafil%Chronic heart failure patients%Pulmonary hypertension
目的 观察左西孟旦联合西地那非治疗慢性心力衰竭合并肺动脉高压患者的疗效.方法 收集2012年6月至2012年12月慢性充血性心力衰竭并肺动脉高压的住院患者30例,随机双盲将患者分为两组,治疗组15例,在常规治疗基础上使用西地那非和左西孟旦,左西孟旦注射液初始以12μg/kg,注射10 min,随即以0.1μg/(kg·min),静脉点滴,持续时间24h,同时应用西地那非25 mg,tid,连续服用30 d,对照组给予常规治疗,如利尿剂、ACEI类、洋地黄类.用药前后化验NT-proBNP,应用美国通用公司的Vingmed vivid7多功能彩色多普勒诊断仪测量左心室射血分数(LVEF)、肺动脉压.结果 治疗组治疗前后LEVF提高(11.110±5.676)％,明显高于 对照组[提高(2.700±1.977)％],差异有统计学意义(t=3.981,P＜0.01),NT-proBNP下降(1844.730±858.340) pg/ml,显著高于对照组[下降(894.470±890.371)pg/nnl],差异有统计学意义(=3.064,P＜0.01),肺动脉压下降(8.400±3.869)mmHg,高于对照组[下降(3.600±3.291) mm Hg],差异有统计学意义(t=3.660,P＜0.01).结论 与常规治疗组相比,左西孟旦联合西地那非治疗老年慢性心力衰竭伴肺动脉压升高患者有效,能显著降低肺动脉压,降低NT-proBNP,改善心功能.
目的 觀察左西孟旦聯閤西地那非治療慢性心力衰竭閤併肺動脈高壓患者的療效.方法 收集2012年6月至2012年12月慢性充血性心力衰竭併肺動脈高壓的住院患者30例,隨機雙盲將患者分為兩組,治療組15例,在常規治療基礎上使用西地那非和左西孟旦,左西孟旦註射液初始以12μg/kg,註射10 min,隨即以0.1μg/(kg·min),靜脈點滴,持續時間24h,同時應用西地那非25 mg,tid,連續服用30 d,對照組給予常規治療,如利尿劑、ACEI類、洋地黃類.用藥前後化驗NT-proBNP,應用美國通用公司的Vingmed vivid7多功能綵色多普勒診斷儀測量左心室射血分數(LVEF)、肺動脈壓.結果 治療組治療前後LEVF提高(11.110±5.676)％,明顯高于 對照組[提高(2.700±1.977)％],差異有統計學意義(t=3.981,P＜0.01),NT-proBNP下降(1844.730±858.340) pg/ml,顯著高于對照組[下降(894.470±890.371)pg/nnl],差異有統計學意義(=3.064,P＜0.01),肺動脈壓下降(8.400±3.869)mmHg,高于對照組[下降(3.600±3.291) mm Hg],差異有統計學意義(t=3.660,P＜0.01).結論 與常規治療組相比,左西孟旦聯閤西地那非治療老年慢性心力衰竭伴肺動脈壓升高患者有效,能顯著降低肺動脈壓,降低NT-proBNP,改善心功能.
목적 관찰좌서맹단연합서지나비치료만성심력쇠갈합병폐동맥고압환자적료효.방법 수집2012년6월지2012년12월만성충혈성심력쇠갈병폐동맥고압적주원환자30례,수궤쌍맹장환자분위량조,치료조15례,재상규치료기출상사용서지나비화좌서맹단,좌서맹단주사액초시이12μg/kg,주사10 min,수즉이0.1μg/(kg·min),정맥점적,지속시간24h,동시응용서지나비25 mg,tid,련속복용30 d,대조조급여상규치료,여이뇨제、ACEI류、양지황류.용약전후화험NT-proBNP,응용미국통용공사적Vingmed vivid7다공능채색다보륵진단의측량좌심실사혈분수(LVEF)、폐동맥압.결과 치료조치료전후LEVF제고(11.110±5.676)％,명현고우 대조조[제고(2.700±1.977)％],차이유통계학의의(t=3.981,P＜0.01),NT-proBNP하강(1844.730±858.340) pg/ml,현저고우대조조[하강(894.470±890.371)pg/nnl],차이유통계학의의(=3.064,P＜0.01),폐동맥압하강(8.400±3.869)mmHg,고우대조조[하강(3.600±3.291) mm Hg],차이유통계학의의(t=3.660,P＜0.01).결론 여상규치료조상비,좌서맹단연합서지나비치료노년만성심력쇠갈반폐동맥압승고환자유효,능현저강저폐동맥압,강저NT-proBNP,개선심공능.
Objective To observe the efficacy of oral sildenafil combined with intravenous levosimendan on patients with chronic heart failure and pulmonary hypertension.Methods From June 2012 to October 2012,18 patients with chronic congestive heart failure and pulmonary hypertension were randomised into control group and treatment group,with 15 cases in each group.In treatment group,on the basis of conventional treatment,patients were given an initial dose of levosimendan of 12 μg/kg,infused over 10 min,followed by a continuous infusion of 0.1 iμg/(kg · min) for 24 h,and oral seldenafil of 75 mg/d for 30 days.The patients in control group were given conventional treatment.NT-proBNP were tested before and after drug therapy,and LVEF and pulmonary artery pressure were measured by Vingmed vivid 7 Multifunctional color Doppler diagnostic instrument.Results In treatment group,LVEF increased higher than that in control group [(11.110 ±5.676)％ vs (2.700 ± 1.977)％],there was significant difference (t =3.981,P ＜ 0.01); NT-proBNP decreased more in treatment group than that in control group[(1844.730 ± 858.340) pg/ml vs (894.470 ± 890.371) pg/ml],there was significant difference (t =3.064,P ＜ 0.01) ; pulmonary artery pressure in treatment group decreased more than that in control group[(8.400 ± 11.344) mm Hg vs (3.600 ±3.291)mm Hg],there was significant difference (t =3.660,P ＜ 0.01).Conclusions Compared with conventional treatment,leosimendan combined with sildenafil could significantly reduce the pulmonary artery pressure and the NT-proBNP in patients with chronic heart failure and pulmonary hypertension,improve cardiac function,so it is effective.
